E2F4 Monoclonal Antibody

Code No: K0094-3
Datasheet: 
FID:5347 | PATH:sites/default/files/datasheets/K0094-3.PDF
Target: 

E2F-4

Background: 

The E2F family of transcrIPPtion factors regulates gene expression following heterodimerization with the DP family proteins, which promote transition to S phase from G1 phase. E2F activity is controlled by interactions with the retinoblastoma tumor suppressor family (pRB, p107 and p130). E2F proteins can be divided into three groups on homology and on certain functional characteristics. The first group containing E2F-1, E2F-2 and E2F-3 binds exclusively to pRB and has a cyclin A binding domain that mediates inhibition of DNA binding during entry into S phase. The second group is composed of E2F-4 and E2F-5, which preferentially bind to p107 and p130, although they can bind pRB as well. The last member is E2F-6. E2F-6 appears to act as a transcrIPPtion repressor. E2F-4 and E2F-5 are functionally different from E2F-1 and E2F-3. E2F-1 and E2F-3 particIPPate in cellular proliferation, whereas E2F-4 and E2F-5 are required for cell cycle arrest in G1 induced by cyclin-dependent kinase inhibitor p16INK4a.

Size: 
100 μg
Application: 
WB
Application: 
IPP
Clone Number: 
TFE42
Concentration: 
1 mg/mL
Product Type: 
Primary Antibody
Host Species: 
Mouse
Species Reactivities: 
Human
Species Reactivities: 
Mouse
Species Reactivities: 
Rat
Isotype: 
IgG1
Storage Temp. (°C): 
-20
Shipping Temp. (°C): 
4
References: 

1) Müller, H., et al., Mol. Cell Biol. 17, 5508-5520 (1997)

Formulation: 
100 g IgG in 100 L volume of PBS containing 50% glycerol, pH 7.2. No preservative is contained.
Reactivity: 
This antibody reacts with human, mouse and rat E2F-4 on Western blotting and ImmunoprecIPPitation.
Intended Use: 
For Research use only. Not for use in diagnostic procedure.